Gapping up
In reaction to strong earnings/guidance: PRSC +22.1%,
CALL +14.9%,
REN +14.6%,
CVSL +11.8%,
WYY +11.8%,
VRTU +9.1%,
ORIG +7.8%,
RGSE +7%,
PLAB +6.2%,
PNX +5.4%,
XON +5%,
NSPH +4.9%,
CHRS +4.4%,
PRKR +4.4%,
NCMI +4.4%,
SCLN +4.3%,
VBLT +3.7%,
ARNA +3.6%,
CPRX +3.5%,
PFSW +3%,
USAT +2.8%,
DTSI +2.7%,
OPHT +2.5%,
SYN +2.4%,
RICK +2.3%,
OVAS +2.1%,
CYTX +2%,
RDY +1.8%,
FF +1.6%,
PRTS +1.5%,
LBMH +1.4%,
INUV +1.4%,
TCRD +1.3%,
ARCO +1.3%,
ELTK +1%,
PFIN +1%,
SCAI +0.8%,
OTIV +0.7%
M&A news: PLL +20.8% (WSJ reporting that Danaher (DHR) and Thermo Fisher Scientific (TMO) may consider possible takeover of PLL), AOL +17.9% (to be acquired by Verizon (VZ) for $50 per share, or ~$4.4 bln),
PRE +2.2% (Exor confirms it has increased its all-cash binding offer to acquire PartnerRe to $137.50 per Share),
VZ +-0.7% (acquired by AOL for $50 per share, or ~$4.4 bln)
Select metals/mining stocks trading higher: MT +2.1%,
ABX +1.6%,
GOLD +1.5%,
GG +1.2%,
GDX +1.1%,
NEM +0.9%,
BHP +0.8%,
SLV +0.7%,
.
Other news: THLD +15.4% (Threshold Pharma and Partner Merck KGaA (MKGAY.PK) receive FDA fast track designation for Evofosfamide, to treat advanced pancreatic cancer),
EOX +10.1% (entered into definitive agreement to acquire core Delaware Basin acreage in Lea and Eddy Counties, New Mexico for $75.2 mln; increases FY15 production and CapEx guidance),
SPPI +8.9% (Armistice Capital discloses 5.4% stake in 13D filing, sends letter to the company requesting it initiate a complete or partial sale),
OCN +7.2% (filed 2014 Form 10-K without a qualification about its ability to operate as a going concern; expects to file its first quarter Form 10-Q on or before May 18),
STM +5.3% (provides investor update in Analyst Day presentations; says back to y/y revenue growth starting from 2H 2015),
NAVB +4.6% secured $60 Million loan with CRG; funding to support Lymphoseek commercialization and advancement of development pipeline),
ARNA +3.6% (co and Roivant Sciences enter into collaboration for nelotanserin, a novel inverse agonist of the 5-HT2A receptor; co also reported earnings),
HK +3.1% (Franklin Resources disclosed 13.5% passive stake in 13G filing),
CDK +2.5% (Elliott Associates disclosed 7.6% active stake in 13D filing),
ZIXI +2.2% (announces share repurchase program of up to $15 mln)
Analyst comments: ANTH +2.5% (upgraded to Neutral from Sell at Citigroup),
SYT +2.2% (upgraded to Mkt Perform from Underperform at Bernstein),
DEG +1.6% (upgraded to Buy from Hold at Jefferies; also confirmed talks with AHONY ),
EW +1.3% (upgraded to Overweight from Neutral at JP Morgan),
JNPR +1% (upgraded to Buy from Neutral at BofA/Merrill)